# A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

> **NCT03276936** · PHASE3 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 504 (actual)

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** FMX103 1.5%

## Key facts

- **NCT ID:** NCT03276936
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2019-01-03
- **Final completion:** 2019-01-15
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276936, "A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03276936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*